Judges Freeze FDA Pill Shift

Louisiana asked a federal appeals court to restore in-person rules for abortion pills, saying the Food and Drug Administration’s mail-order policy is unlawful and has harmed women in the state.

Story Snapshot

Louisiana seeks to block the Food and Drug Administration’s 2023 mail-order abortion pill policy through the courts.
The state cites Medicaid costs and several patient harm cases to claim legal standing and urgency.
A Fifth Circuit order summarized Louisiana’s claims and paused parts of the federal policy during the case.
The lawsuit highlights a larger fight over who sets drug and abortion rules after the Dobbs decision.

What Louisiana Is Asking the Court to Do

Louisiana’s lawsuit asks a federal court to declare the Food and Drug Administration’s 2023 changes to the Risk Evaluation and Mitigation Strategy for mifepristone unlawful. The state seeks to vacate that policy and reinstate in-person dispensing rules nationwide. The complaint also requests preliminary and permanent injunctions to stop mail and telehealth distribution while the case proceeds. The filing names the Food and Drug Administration and related officials, and includes a private plaintiff, Rosalie Markezich, alongside the state.

A panel of the United States Court of Appeals for the Fifth Circuit later issued a stay affecting the 2023 policy while litigation continues. The order summarized Louisiana’s claims, including “numerous illegal abortions in Louisiana” and state Medicaid payments tied to complications from mifepristone. The stay described the state’s theory of harm and allowed the case to proceed on an accelerated track. The court’s action signals that judges see live legal questions about the Food and Drug Administration’s 2023 approach.

How Louisiana Says It Was Harmed

Louisiana argues it has standing because it pays for emergency care through Medicaid when residents suffer complications. A filing by Danco Laboratories to the Supreme Court recounted the Fifth Circuit’s description of the state’s claimed costs, including about $92,000 linked to two 2025 emergency cases. State officials also say they have documented several women harmed or “poisoned” by abortion pills obtained by mail or telehealth, and urge a return to in-person safeguards.

The complaint also highlights the named plaintiff’s account to show risks from easier access. Reports say Rosalie Markezich alleges a former partner obtained the drug and coerced her to take it. Louisiana frames this as evidence that mail or remote prescribing weakens screening and control steps that in-person visits can provide. Attorney General Liz Murrill has publicly called the pre-2023 rules “good common sense” and wants those checks restored for patient safety.

What Changed in the Food and Drug Administration’s 2023 Policy

The Food and Drug Administration modified the mifepristone Risk Evaluation and Mitigation Strategy in 2023, allowing certified pharmacies to dispense by mail and enabling telehealth prescribing under certain conditions. The agency’s official summary review documents the change and ties it to the broader Risk Evaluation and Mitigation Strategy program that dates to 2019 for mifepristone. Supporters of the change say it reflected agency judgment after years of monitoring and review of safety and access.

Since the Dobbs ruling, policy fights over abortion have often moved to federal courts and focused on who decides the rules. This case blends that post-Dobbs pattern with a classic drug-law dispute: one side pushes specific harm stories to justify tighter controls, while the other side points to the Food and Drug Administration’s long-running oversight and the challenge of drawing broad conclusions from a small number of cases. Those legal frames now drive much of the public health debate.

Why the Case Matters Beyond Louisiana

A ruling against the Food and Drug Administration could restrict how abortion pills are prescribed and dispensed nationwide, not just in Louisiana. That would change how telehealth providers, pharmacies, and patients interact in many states. The case already drew support from 21 attorneys general and 60 members of Congress who filed friend-of-the-court briefs backing Louisiana’s position. The scale of that support shows interest among officials who want tighter federal limits on mail-order abortion pills.

She said no.

No to the abortion. No to the pills. No to ending a baby she already loved.

In October 2023, Rosalie's then-boyfriend used her information to order abortion pills from an out-of-state doctor. The pack showed up at her Louisiana door.

She has said he cornered her,… pic.twitter.com/I63un6VekX

— Americans United for Life (@AUL) September 10, 2026

The stakes also involve costs and trust in federal oversight. Many conservatives see the mail policy as a shortcut that risks women’s health and shifts bills onto state programs. Many liberals see it as needed access, especially in areas with few clinics. A growing share on both sides worry that distant agencies and political actors put power first. This lawsuit tests whether courts will force the Food and Drug Administration to slow down and show more guardrails, or affirm its recent direction.